Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling
- 223 Downloads
Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer with high metastatic potential. Most patients have lymph node involvement at the time of diagnosis and 1/3 of the patients have distant metastases. In a previous study, we demonstrated that IBC is a distinct form of breast cancer in comparison with non-IBC. The aim of this study was to investigate the presence of the different molecular subtypes in our data set of 16 IBC and 18 non-IBC specimen. Therefore, we selected an ‘intrinsic gene set’ of 144 genes, present on our cDNA chips and common to the ‘intrinsic gene set’ described by Sorlie et al. [PNAS, 2003]. This set of genes was tested for performance in the Norway/Stanford data set by unsupervised hierarchical clustering. Expression centroids were then calculated for the core members of each of the five subclasses in the Norway/Stanford data set and used to classify our own specimens by calculating Spearman correlations between each sample and each centroid. We identified the same cell-of-origin subtypes in IBC as those already described in non-IBC. The classification was in good agreement with immunohistochemical data for estrogen receptor protein expression and cytokeratin 5/6 protein expression. Confirmation was done by an alternative unsupervised hierarchical clustering method. The robustness of this classification was assessed by an unsupervised hierarchical clustering with an alternative gene set of 141 genes related to the cell-of-origin subtypes, selected using a discriminating score and iterative random permutation testing. The contribution of the different cell-of-origin subtypes to the IBC phenotype was investigated by principal component analysis. Generally, the combined ErbB2-overexpressing and basal-like cluster was more expressed in IBC compared to non-IBC, whereas the combined luminal A, luminal B and normal-like cluster was more pronounced in non-IBC compared to IBC. The presence of the same molecular cell-of-origin subtypes in IBC as in non-IBC does not exclude the specific molecular nature of IBC, since gene lists that characterize IBC and non-IBC are entirely different from gene lists that define the different cell-of-origin subtypes, as evidenced by principal component analysis.
Keywordscell-of-origin subtypes gene-expression profiling imflammatory breast cancer microarray
Unable to display preview. Download preview PDF.
We would like to thank Professor Charles M. Perou of the Departments of Genetics and Pathology at the Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill for his contribution to the data analysis and for critically reading the manuscript. Gert Van den Eynden is a research assistant of the Fund for Scientific Research Flanders, Belgium. Steven Van Laere is supported by a Research Grant of the University Hospital Antwerp (University of Antwerp, Wilrijk, Belgium). Supported by grant G.0100.04 of the Fund for Scientific Research Flanders, Belgium.
- 2.Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D, 2000 Molecular portraits of human breast tumors Nature 406: 747–752CrossRefPubMedGoogle Scholar
- 3.Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL, 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98: 10869–10874CrossRefPubMedGoogle Scholar
- 4.Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D, 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100: 8418–8423CrossRefPubMedGoogle Scholar
- 9.American Joint Committee on Cancer 2002 AJCC Cancer Staging Manual Sixth Edition. Springer Verlag, New York, Berlin, Heidelberg p. 221–240Google Scholar
- 11.Van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD, 1999 A novel putative low-affinity insulin-like growth factor binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype Clin Cancer Res 5: 2511–2519PubMedGoogle Scholar
- 12.Van den Eynden GG, Van der Auwera I, Van Laere S, Colpaert CG, van Dam P, Merajver S, Kleer CG, Harris AL, Van Marck EA, Dirix LY, Vermeulen PB, 2004 Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer Breast Cancer Res Treat 85: 13–22CrossRefPubMedGoogle Scholar
- 20.Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Roy F, van Beest P, Goovaerts G, Dirix LY, van Dam P, Fox SB, Harris AL, van Marck EA, 2003 Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression Br J Cancer 88: 718–725CrossRefPubMedGoogle Scholar
- 21.Van der Auwera I, Van Laere SJ, Van den Eynden GC, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, Vermeulen PB, Dirix LY, 2004 Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification Clin Cancer Res 10: 7965–7971CrossRefPubMedGoogle Scholar
- 22.Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerlo J, Tagett R, Tarpin C, Houvenaeghel G, Nguyen C, Maraninchi D, Jacquemier J, Houlgatte R, Birnbaum D, Viens P, 2004 Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy Cancer Res 64: 8558–8565CrossRefPubMedGoogle Scholar
- 23.Van Laere SJ, Van der Auwera I, Van den Eynden GG, Fox SB, Bianchi F, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY, 2005 Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis Breast Cancer Res Treat, accepted for publicationGoogle Scholar
- 26.Magrangeas F, Nasser V, Avet-Loiseau H, Loriod B, Decaux O, Granjeaud S, Bertucci F, Birnbaum D, Nguyen C, Harousseau JL, Bataille R, Houlgatte R, Minvielle S, 2003 Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease Blood 101: 4998–5006CrossRefPubMedGoogle Scholar
- 27.Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM, 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10: 5367–5374CrossRefPubMedGoogle Scholar
- 29.Tsuda H, Morita D, Kimura M, Shinto E, Ohtsuka Y, Matsubara O, Inazawa J, Tamaki K, Mochizuki H, Tamai S, Hiraide H, 2005 Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation Cancer Sci 96: 48–53PubMedGoogle Scholar